Acrivon (ACRV) director receives 9,366 restricted stock units as equity award

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. director Michael John Tomsicek reported an equity compensation grant. He acquired 9,366 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost. Each RSU represents one share, and the award vests in full on May 18, 2027, subject to his continuous service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider TOMSICEK MICHAEL JOHN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,366	$0.00	--

Holdings After Transaction: Common Stock — 9,366 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 9,366 units Grant price per share: $0.00 per share Holdings after transaction: 9,366 shares +1 more

4 metrics

RSU grant size 9,366 units Restricted stock units representing common shares

Grant price per share $0.00 per share Equity compensation, not market purchase

Holdings after transaction 9,366 shares Direct ownership following RSU grant

RSU vesting date May 18, 2027 RSUs vest in full on this date

Key Terms

restricted stock units, RSUs, continuous service

3 terms

restricted stock units financial

"These shares represent restricted stock units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Each RSU represents a contingent right to receive one share"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TOMSICEK MICHAEL JOHN

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A(1)		9,366	A	$0	9,366	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Acrivon Therapeutics (ACRV) director Michael Tomsicek report on this Form 4?

Michael John Tomsicek reported receiving 9,366 restricted stock units of Acrivon Therapeutics common stock. This is an equity compensation grant, not an open-market purchase or sale, and represents a contingent right to receive shares in the future, subject to vesting.

How many ACRV shares are covered by Michael Tomsicek’s RSU grant?

The grant covers 9,366 restricted stock units, each tied to one Acrivon Therapeutics common share. According to the filing, following this transaction he holds 9,366 shares directly, reflecting the full amount of the reported RSU award.

When do Michael Tomsicek’s Acrivon Therapeutics RSUs vest?

The RSUs are scheduled to vest in full on May 18, 2027. Vesting is contingent on Michael Tomsicek’s continuous service with Acrivon Therapeutics through that date, meaning the shares are not deliverable before this time if service ends.

Did Michael Tomsicek buy or sell ACRV stock in the market?

No, the Form 4 shows a grant of restricted stock units, not a market trade. The transaction is coded as a grant or award acquisition at a price of $0.00 per share, reflecting compensation rather than an open-market purchase or sale.

What does it mean that each ACRV RSU represents one share of common stock?

Each restricted stock unit represents a contingent right to receive one share of Acrivon Therapeutics common stock. Shares are delivered only when the RSUs vest, in this case on May 18, 2027, assuming the continuous service condition is satisfied.